Other languages BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Delayed Nasdaq Other stock markets 03:53:57 2024-05-30 pm EDT			5-day change	1st Jan Change
28.81 ^USD	+4.35%		+3.75%	-28.66%

May. 29	Transcript : BridgeBio Pharma, Inc. - Special Call
May. 28	UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population	May. 13
BridgeBio Pharma Shares Decline After Q1 Financial Results	May. 02
BridgeBio Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	Apr. 07
BridgeBio Pharma Prices $250 Million Stock Offering	Mar. 06
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05
BridgeBio Pharma Commences $250 Million Share Offering	Mar. 04
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	Mar. 04
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	Mar. 04
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	Feb. 22
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
KKR to acquire a stake in health tech firm Cotiviti	Feb. 14
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan	Feb. 07
Bridgebio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	Feb. 07
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy	Feb. 05
AstraZeneca Says Phase 3 Trial of Acoramidis in Japan Well-Tolerated; Shows Consistency With Global Trial	Feb. 02
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months	Feb. 02
AstraZeneca : essai positif dans l'amylose cardiaque	Feb. 02
AstraZeneca celebrates latest successful trial of acoramidis in Japan	Feb. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Other languages

Filters